Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board – Yahoo Finance

PRINCETON, NJ / ACCESSWIRE / April 6, 2020 / Sonnet BioTherapeutics Holdings, Inc. (SONN), a biopharmaceutical company developing innovative, targeted biologic drugs with enhanced single or bispecific mechanisms of action, announced today the formation of its Scientific Advisory Board. The Board comprises experts from leading institutions across the United States, including MD Anderson, Memorial Sloan-Kettering, Fox Chase and Robert Wood Johnson. The members bring decades of experience in oncology, neurology, drug discovery and clinical development.

"Sonnet is privileged to have this distinguished group of scientific advisors from leading institutions to help guide our clinical development and discovery programs," commented Sonnet Founder and CEO, Pankaj Mohan, Ph.D. "The advisors come to the company after reviewing its assets and are excited to be a part of the team. They share deep experience in oncology drug development from initial discovery to late-stage clinical studies, which will enhance our strategic efforts through the next phase of growth."

Sonnet Scientific Advisory Board members include:

Jason Bock, Ph.D., - Dr. Bock is the Vice President and Head of Biologics Product Development at MD Anderson Cancer Center. In this role, Dr. Bock works with MD Anderson's Therapeutic Discovery team, including world-class oncology researchers and clinicians, to create life-saving transformational medicines quickly, safely and effectively. Before joining MD Anderson, Dr. Bock spent 20 years in small, medium and large biotech and biopharma companies (including Human Genome Sciences, CoGenesys and TEVA) developing biologic therapeutics. He has brought 15 novel drugs through preclinical development into clinical studies and has guided the process to bring three biologics through the clinic and to commercialization globally. He received his Ph.D. from Stanford University in Molecular & Cellular Physiology.

Joseph R. Bertino, M.D., - Dr. Bertino is University Professor of medicine and pharmacology, UMDNJ-Robert Wood Johnson Medical School and is the interim director of the school's Cancer Institute of New Jersey. Dr. Bertino joined The Cancer Institute of New Jersey in 2002 as associate director and was appointed chief scientific officer in 2004. Previously, Dr. Bertino served as chair of the Molecular Pharmacology and Therapeutics Program, and member and co-head of the Program in Developmental Therapy and Clinical Investigation at Memorial Sloan-Kettering Institute for Cancer Research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. He is the author or co-author of more than 400 scientific publications and the associate medical editor of the journal Hem/Onc Today. After earning his medical degree, Dr. Bertino did a USPHS fellowship in hematology and oncology at the University of Washington School of Medicine.

Hossein Borghaei, D.O., M.S., - Dr. Borghaei is Chief of Thoracic Medical Oncology at Fox Chase Cancer Center, where he is also a Professor in the Department of Oncology/Hematology, Co-Director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies. In his clinical practice, Dr. Borghaei has participated in numerous immunotherapy-based clinical trials. He is also the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting. Dr. Borghaei earned his D.O. degree at Philadelphia College of Osteopathic Medicine, did his residency at Graduate Hospital (Philadelphia) and was Chief Fellow, Hematology-Oncology, at Fox Chase Cancer Center.

Guido Cavaletti, M.D., - Dr. Cavaletti is Dean of Research and Professor at the University of Milan-Bicocco, and Senior consultant neurologist and head of the Neuroimmunology Center, S. Gerardo Hospital, Monza (Italy). At the University of Milan-Bicocco, he is Head of the Experimental Neurology Unit at the School of Medicine and Surgery and Director of the Ph.D. program in Neuroscience. He is also Deputy Scientific Director of the Milan Center for Neuroscience (NeuroMI). Dr. Cavaletti is coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity. He has authored more than 250 peer-reviewed papers. He received his medical degree from the University of Milan and is Board-certified in Neurology.

Story continues

About Sonnet BioTherapeutics Holdings, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Alan LadaSolebury Trout617-221-8006alada@soleburytrout.com

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/583990/Sonnet-BioTherapeutics-Announces-Formation-of-Scientific-Advisory-Board

More:
Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board - Yahoo Finance

Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness – Neurology Advisor

Dolutegravir (DTG) discontinuation due toneuropsychologic side effects (NPS) may be associated with preexistingpsychiatric conditions of depression and anxiety, according to results of astudy presented at the virtual Conference on Retroviruses and OpportunisticInfections, held from March 8 to 11, 2020.

DTG treatment has been associated with a higherrate for discontinuation as a result of NPS. Several associated factors forthis association have been described, including older age, female sex, abacavircoadministration, higher DTG exposure, and pharmacokinetic- and pharmacodynamic-mediatedvariants. In addition, there has been an observed increase in the rates ofmoderate depression among patients who have switched to DTG. However,pre-existing psychiatric disorders have not previously been associated with ahigher risk for NPS. Therefore, this prospective, observational study describedthe clinical features and outcomes of patients stopping DTG for NPS.

In total, 1455 participants starting DTG (naive and treated) were included from 2 Italian outpatient clinics. Clinical, therapeutic pharmacokinetics variables with the risk for DTG discontinuation due to NPS were analyzed. This analysis focused on patients who stopped DTG for NPS in terms of pre-existing psychiatric comorbidities and outcomes after drug withdrawal (resolution of symptoms was recorded at the first available follow-up after discontinuation).

Of all included participants, after a median of5.1 months, 526 participants discontinued DTG, with the most common reasonbeing treatment switches with no efficacy or tolerability issues (n=274); 66(4.5%) of participants discontinued DTG due to NPS. Of the 66 participants whodiscontinued DTG due to NPS, 21 (31.8%) participants had pre-existingpsychiatric conditions, with the 2 most common being depression (12 [18.2%]patients) and anxiety (4 [6.1%] patients).

The most common symptoms according to the preexisting psychiatric comorbidities of depression and anxiety were sleep disorders (35.6%), anxiety (28.9%), and headache (24.4%). Both headache (P =.039) and sleep disorders (P =.083) were associated with complete resolution of symptoms. After discontinuation, DTG was replaced with raltegravir (n=20), elvitegravir/c (n=19), darunavir/c (n=17), or rilpivirine (n=8), with the most complete resolution of symptoms observed with the elvitegravir/c replacement and the converse observed among patients who received rilpivirine.

Overall, the study concluded that NPS wereheterogeneous, with sleep disorders, headache, and anxiety being the moreincident among such effects, and no signal for a better switching strategyemerged.

Reference

Andrea C, Borghetti A, Milesi M, et al. Clinical features and outcomes of patients stopping STG for neuropsychiatric symptoms. Poster presented at: CROI 2020; March 8-11, 2020; Boston, MA. http://www.croiconference.org/sites/default/files/uploads/croi2020-boston-abstract-ebook.pdf. Accessed March 27, 2020.

This article originally appeared on Infectious Disease Advisor

Follow this link:
Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness - Neurology Advisor

Cannabidiol as an Adjunctive Therapy for Patients With Treatment-Resistant Dravet Syndrome – Neurology Advisor

Cannabidiol daily doses of 10 or 20 mg/kg can be a safe and effective adjunct treatment to reduce seizure in patients with highly resistant Dravet syndrome, according to study results published in JAMA Neurology.

Previous studies have supported the safety and efficacy of cannabidiol at a daily dose of 20 mg/kg as an add-on antiepileptic treatment in patients with Dravet syndrome. The goal of the current study was to assess the efficacy and safety of 2 daily doses of cannabidiol, 10 mg/kg or 20 mg/kg, in children with Dravet syndrome.

The double-blind, placebo-controlled, randomized clinical trial included children aged 2 to 18 years from 38 centers in the United States, Spain, Poland, the Netherlands, Australia, and Israel with a confirmed diagnosis of Dravet syndrome and at least 4 convulsive seizures during a 4-week baseline period while receiving antiepileptic therapy.

The patients were randomly assigned to receive cannabidiol oral solution at a daily dose of 10 (CBD10) or 20 (CBD20) mg/kg, or matched placebo in 2 equally divided doses for 14 weeks. The primary outcome was the change in the frequency of convulsive seizure frequency from baseline.

A total of 198 patients (mean age, 9.3 years; 52.5% girls) were enrolled in the study; of these, 65 received placebo, 66 received CBD10, and 67 received CBD20. A total of 190 patients completed the treatment period, and 186 (97.9%) entered the open-label extension trial.

Convulsive seizure frequency compared with baseline was reduced by 48.7% in the CBD10 group and by 45.7% in the CBD20 group compared with 26.9% in the placebo group. The percentage reduction from placebo was 29.8% (95% CI, 8.4%-46.2%; P =.01) for the CBD10 group and 25.7% (95%CI, 2.9%-43.2%; P =.03) for the CBD20 group.

The most common adverse events occurring in 10% of patients in any group included decreased appetite, diarrhea, somnolence, pyrexia, and fatigue. Serious adverse events occurred in 40 patients (10 in the placebo group, 13 in the CBD10 group, and 17 in the CBD20 group). Elevated liver transaminase levels occurred more frequently in the CBD20 (n=13) than the CBD10 (n=3) group, with all affected patients receiving concomitant valproate sodium.

The study had several limitations, according to the researchers, including the short-term follow-up period, limited option to assess the effects of specific drug combinations as cannabidiol was added to various antiepileptic regimens, and lack of data on the safety and efficacy of cannabidiol in daily doses <10 mg/kg.

Our key finding is the significant and clinically meaningful reduction of seizures with an acceptable safety profile for both cannabidiol doses in patients with highly treatment-resistant Dravet syndrome, concluded the researchers.

Disclosure: This clinical trial was supported by GW Research, Ltd. Please see the original reference for a full list of authors disclosures

Reference

Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial [published online March 2, 2020]. JAMA Neurol. doi:10.1001/jamaneurol.2020.0073

Read more:
Cannabidiol as an Adjunctive Therapy for Patients With Treatment-Resistant Dravet Syndrome - Neurology Advisor

Dr. James T. Goodrich, Who Operated on Conjoined Twins, Dies at 73 – The New York Times

This obituary is part of a series about people who have died in the coronavirus pandemic.

Dr. James T. Goodrich, a pediatric neurosurgeon known for successfully separating conjoined twins in a complicated and rare procedure, died on Monday at Albert Einstein College of Medicine and Montefiore Medical Center in the Bronx. He was 73.

The cause was complications of the coronavirus, according to Montefiore, where he was the director of pediatric neurosurgery and had spent more than 30 years of his career.

Dr. Goodrich was thrust into public view when he conducted a series of four operations over nearly a year on Clarence and Carl Aguirre, twins from the Philippines who were joined at the tops of their heads and shared major veins in their brains. Dr. Goodrich led a team of surgeons at Montefiores Childrens Hospital, and the twins story generated headlines, including in The New York Times, and was the subject of television specials.

During the final surgery, in August 2004, the team discovered that the twins brains were connected by more brain tissue than they had initially thought, a potentially serious complication.

We got to this point and we were stuck, Dr. Goodrich told The Times after the operation, but we did a lot of soul-searching and decided to continue.

Hours later, Clarence and Carl lay next to each other, alive and well. They had no major complications after the surgery, and their mother, Arlene Aguirre, said, My dream has come true.

Carl and Clarence, who turn 18 later this month, live with their mother in Scarsdale, N.Y.

James Tait Goodrich was born in Portland, Ore., on April 16, 1946, to Richard and Gail (Josselyn) Goodrich. His mother was an artist and a designer, and his father worked in advertising. Dr. Goodrich served in the Marines during the Vietnam War, then studied neurosurgery and psychobiology at the University of California, Irvine; Columbia University; and the Neurological Institute of New York before starting at Montefiore.

He married Judy Laudin in 1970. In addition to his wife, he is survived by three sisters, Kristine Goodrich, Jan Rentenaar and Carol Montecucco.

In another celebrated case, Dr. Goodrich led a team of 40 surgeons in a 27-hour procedure in 2016 to separate another set of twin boys, the seventh separation procedure of his long career.

Read this article:
Dr. James T. Goodrich, Who Operated on Conjoined Twins, Dies at 73 - The New York Times

Coronavirus: Ministry will monitor any reports of test price cheats – Cyprus Mail

What Are Cookies

As is common practice with almost all professional websites, our site uses cookies, which are tiny files that are downloaded to your device, to improve your experience.

This document describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or break certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately, in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to the site. It is recommended that you leave on all cookies if you are not sure whether you need them or not, in case they are used to provide a service that you use.

The types of cookies used on this website can be classified into one of three categories:

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browsers Help option on how to do this). Be aware that disabling cookies may affect the functionality of this and many other websites that you visit. Therefore, it is recommended that you do not disable cookies.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. Our site uses [Google Analytics] which is one of the most widespread and trusted analytics solutions on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so that we can continue to produce engaging content. For more information on Google Analytics cookies, see the official Google Analytics page.

Google Analytics

Google Analytics is Googles analytics tool that helps our website to understand how visitors engage with their properties. It may use a set of cookies to collect information and report website usage statistics without personally identifying individual visitors to Google. The main cookie used by Google Analytics is the __ga cookie.

In addition to reporting website usage statistics, Google Analytics can also be used, together with some of the advertising cookies, to help show more relevant ads on Google properties (like Google Search) and across the web and to measure interactions with the ads Google shows.

Learn more about Analytics cookies and privacy information.

Use of IP Addresses.An IP address is a numeric code that identifies your device on the Internet. We might use your IP address and browser type to help analyze usage patterns and diagnose problems on this website and to improve the service we offer to you. But without additional information your IP address does not identify you as an individual.

Your Choice.When you accessed this website, our cookies were sent to your web browser and stored on your device. By using our website,you agree to the use of cookies and similar technologies.

More Information

Hopefully the above information has clarified things for you. As it was previously mentioned, if you are not sure whether you want to allow the cookies or not, it is usually safer to leave cookies enabled in case it interacts with one of the features you use on our site. However, if you are still looking for more information, then feel free to contact us via email at [emailprotected]

Continue reading here:
Coronavirus: Ministry will monitor any reports of test price cheats - Cyprus Mail

London-based Brookstreet Equity and Its Greek Tech Investments Are Fighting Coronavirus – Yahoo Finance

LONDON, April 6, 2020 /PRNewswire/ -- Brookstreet Equity Partners (Brookstreet), a London-based PEVC investor, is joining the fight against Coronavirus (COVID-19) with the support of its technology portfolio assets in Greece, including Terracom software, Gizelis Robotics and NanoPhos nano-tech.

Terracom, of Ioannina, took the initiative to offer their QR-Patrol & MyLoneWorkers workforce management solutions for free for the remaining of the year to all healthcare institutions worldwide. Terracom is a global technology firm that has developed the renowned QR-Patrol and MyLoneWorkers integrated, cloud-based, software-as-a-service (SaaS) workforce management platforms. The company is entrusted by clients in 82 countries, including Heathrow Airport, GS4, Brinks, Securitas, Carnegie Mellon, Hilton, and IKEA. They believe hospitals can leverage their solutions to manage their workforce more effectively, save time and resources, and channel efforts where they matter most, saving lives.

https://www.terracom.gr/en/covid19

Gizelis Robotics, of Schimatiri, an Industry 4.0 and artificial intelligence integrator, is designing and preparing for production an ultraviolet (UV) disinfection robot for hospitals and factories. Robots are particularly relevant during the Coronavirus outbreak to help manufacturers, small and large, to retain their production. The company's products and services range from full factory automation to small batch processing, for example using robots in hospitals to deliver medicine, in supermarkets for palletising and in factories for welding and handling.

https://grobotics.eu

NanoPhos, of Lavrio, is an innovative, award-winning "smart" coatings manufacturer. They offer a range of diversified nano-technology solutions in energy, marine and construction industries. The company is producing Energy Boosting coatings which can increase the capacity of photovoltaics by up to 8%, thereby helping the electricity grids and supplies shipping firms with friction-reducing nano-coatings worldwide. Latterly, NanoPhos is supporting the Greek market by using part of its production capacity for nano-enhanced health sanitisers.

https://nanophos.com/eng/

Brookstreet's Managing Partner, Omiros D. Sarikas, commented,"Our CEOs and their teams are working tirelessly on initiatives and innovative solutions that will help us win the fight against Coronavirus ... we are all in this together and every day we try to do more for our communities and customers."

About:Brookstreet invests in high-growth, export-driven, innovative small-cap outperformers. Its differentiated strategy focuses on providing private capital, together with day-to-day commercial support and an international platform. The fund manager pioneers the development of the UK's best-in-class private equity model in asymmetric markets. Brookstreet has received numerous awards including being recognised as a Real Deals DraxFuture40 investor that helps shape the future of Europe.

Registered and Regulated by the Financial Conduct Authority (FCA) Member of the British Private Equity and Venture Capital Association (BVCA)

Press:For interviews with Brookstreet and any inquiries with Terracom, Gizelis Robotics or NanoPhos please contact Davinia Smith, T: +44 (0) 207 129 1235, E: dsmith@brookstreetequity.com

Brookstreet Equity Partners LLP42 Brook StreetMayfair, London W1K 5DB,UKPhone: +44 (0) 207 129 1235Website: http://www.brookstreetequity.com Email: info@brookstreetequity.com

View original content:http://www.prnewswire.com/news-releases/london-based-brookstreet-equity-and-its-greek-tech-investments-are-fighting-coronavirus-301035403.html

SOURCE Brookstreet Equity Partners

See the rest here:
London-based Brookstreet Equity and Its Greek Tech Investments Are Fighting Coronavirus - Yahoo Finance

Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) – Publicist360

Global Nano Therapy Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 8.6% during a forecast period.

Global Nano Therapy Market

Market Dynamics

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanotherapy is a branch of Nano medicine that includes using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process called as targeting.

This report provides insights into the factors that are driving and restraining the global Nano Therapy market. Nanotherapy is also referred to as targeted therapy, which offers to transport the molecules to the affected cells to treat the disease without affecting other negative effects on the healthy cells. Nanoparticles allow for multiple functional groups to be added to the surface. Each of the functional groups contributes to the effectiveness of this method of therapy and deliver its components in a controlled way once it gets to the target cells/tissue. Nano therapy is considered as recent technology for some diseases, which are implemented with the help of submicron-sized molecular devices or nanoparticles. Nanoparticles can improve the drug accessibility in the body with strength, drag out the medication, and can upsurge the half-life of plasma and boost the drug specificity. These are the factors driving the growth of the Nano therapy market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/54507

As compared to the conventional methods, this method has increased more popularity owing to its high accuracy when it comes to administering therapeutic formulations. The market is thriving, with around 250 Nano-medical products being verified or used for humans. Though, with Nano therapy, the carrier is protected from degradations, which allows it to reach given target cells in the body for a local reaction. Nano therapy is considerably used in the treatment of diseases like cancer, diabetes, and cardiovascular diseases. A recent study by the Journal of Diabetes and Metabolic diseases has stated that the incidence of MS ranged from 30.5 to 31.5% in China and 35.8 to 45.3% in India.

However, an absence of controlling standards in the examination of Nano therapy and high expenditure of treatment are several of the major factors that are restraining the growth of the Nano therapy market during the forecast period.

Global Nano Therapy Market Segment analysis

Based on Type, the Nanomaterial segment is anticipated to grow at a CAGR of 20.8% during the forecast period. The nanomaterial is the materials with at least one exterior dimension in the size range of nearly 1 to 100 nanometers. The nanomaterial is intended for developing novel characteristics and has the potential to improve quality of life. The nanomaterial is generally used in cosmetics, healthcare, electronics, and other areas currently. Unceasing development and innovation in the field are impelling the growth of the global nanomaterials market. The amazing chemical and physical properties of materials at the nanometer scale allow novel applications. For instance, energy conservation and structural strength improvement to antimicrobial properties and self-cleaning surfaces. Nanotechnology is being increasingly efficient by spending mainly on R&D activities which are resulting in the development of current technologies and innovations with reference to the new materials.

Global Nano Therapy Market Regional analysis

North America region dominated the Nano therapy market with US$ XX Mn in 2019. The availability of technology, increasing healthcare spending, and government funding for research and development are some of the factors boosting the growth of the Nano therapy market in the region. Europe is expected to follow the Americas and bring in the second leading market share for Nano therapy throughout the forecast period. Europe is mainly driven by awareness and improvement in the nanotechnology sector.

Recent Developments

In 08 May 2019- Cisplatin cis-(diammine) dichloridoplatinum (II) (CDDP) is the first platinum based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck.

In May 2019- A new study conducted by scientists from the Indian Institute of Technology, Bombay, have designed hybrid nanoparticles to treat cancer. These nanoparticles are made from gold and lipids. These nanoparticles respond to light and can be directed inside the body to release drugs to a targeted area, and are biocompatible, meaning theyre not toxic to a human body.

In September 2019, researchers at Finlands University of Helsinki, in partnership with the bo Akademi University and Chinas Huazhong University of Science and Technology developed an anti-cancer nanomedicine useful for targeted cancer chemotherapy.

The objective of the report is to present a comprehensive analysis of the Global Nano Therapy Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Nano Therapy Market dynamics, structure by analyzing the market segments and project the Global Nano Therapy Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Nano Therapy Market make the report investors guide.Scope of the Global Nano Therapy Market

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/54507

Global Nano Therapy Market, By Type

Nanomaterial and Biological Device Nano Electronic Biosensor Molecular Nanotechnology Implantable Cardioverter-DefibrillatorsGlobal Nano Therapy Market, By Application

Cardiovascular Disease Cancer Therapy Diabetes Treatment Rheumatoid ArthritisGlobal Nano Therapy Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Nano Therapy Market

Selecta Biosciences Inc. Cristal Therapeutics Sirnaomics Inc. Nanobiotix Luna CytImmune Science Inc. NanoBio Corporation Nanospectra Biosciences Inc. Nanoprobes Inc. NanoBioMagnetics.n.nu Smith and Nephew NanoMedia Solutions Inc. Nanosphere Inc. DIM Parvus Therapeutics Tarveda Therapeutics

MAJOR TOC OF THE REPORT

Chapter One: Nano Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nano Therapy Market Competition, by Players

Chapter Four: Global Nano Therapy Market Size by Regions

Chapter Five: North America Nano Therapy Revenue by Countries

Chapter Six: Europe Nano Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Nano Therapy Revenue by Countries

Chapter Eight: South America Nano Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nano Therapy by Countries

Chapter Ten: Global Nano Therapy Market Segment by Type

Chapter Eleven: Global Nano Therapy Market Segment by Application

Chapter Twelve: Global Nano Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nano Therapy Market Report at: https://www.maximizemarketresearch.com/market-report/global-nano-therapy-market/54507/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more:
Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Publicist360

Reusable respirators protect doctors and nurses against coronavirus, they aren’t in the national stockpile – MetroWest Daily News

Reusable respirator masks could be a lifeline for health careworkerstrying toprotect themselveswhiletreatingcoronavirus patients.

Theyprovidethesamelevel ofprotection as disposableN95 respirators,which arein short supply around theworld.Theycan beeasily disinfected between patients and shifts. And theylast for months.

But thenationsemergency supply of medicalequipment never stocked them,despiteyears of research predicting direshortfalls of disposablerespirators during a pandemic andrecommendations to stockpilereusableones.

Thedecision not to buy them for the Strategic National Stockpileis inexplicabletoTomFrieden,who led theU.S.Centers forDiseaseControland Preventionuntil 2017.

You can get oneto a health careworker and say,Here's how you clean it and it's yours for theduration of thepandemic, Friedentold USA TODAY. And thoseareon themarket."

Hesaid theCDC predicted as many as 4 billion disposablemasks would beneededin anemergency liketheonethecountry faces now.

An official at theDepartment of Health and Human Services, which oversees thestockpile,said not buying thereusablerespirators was a matter of balancing funding and priorities.

The stockpile hasan alternativeto disposable masks,the official said: battery-powered, air-purifyingmasks.Butthe official,who declined to be identified without authorization,declined to say how many of those are in stock.

Thosedevices, which blow air into the users faces, can becomplicated, noisy and costly.Theyrun$500to $800apiecemany timesmore thana reusable respirator,according to astudyby researchers at the U.S. Department of Veterans Affairspublished in 2015.

Reusablerespirators costbetween$25 and $50;the disposable ones are 25to65 centseach.

In addition to disposable masks, that study recommended stockpiling reusablerespiratorsover air-purifying devices because they cost less and are easier touse.

Officials running thenational stockpileshould havebought reusablerespirators,said Lisa Pompeii, a researcherat Baylor Collegeof Medicine.

Pompeiiis theleadauthor of a study published last week that concluded health careworkers could bequickly fittedfor reusablerespirators and trained on how to usethem.

Theneed is moreurgent thanever.Almost 20% of health careproviders surveyed a weekagohadnorespirators.Another 28% said they werealmost out, according totheAssociation for Professionals in Infection Control andEpidemiology.

Its so discouraging,thesituation wefind ourselves in,said Ann MariePettis, theassociations president-elect.Wereout theretrying to help thosewho aretruly on thefront lines to help them besafeand keep their families safe.

But "so much of what wenormally teach is having to bethrown out thewindow becauseof thelack of supplies, shesaid. Theres all theseweird things weretelling peoplethey can do, suchasreusing disposablemasks.

TheJoint Commission, which accredits hospitals nationwide,altereditspolicyon protectiveequipmentTuesday to allowtheuseof homemademasksan extrememeasureto betaken onlywhenstandardequipmentis unavailable.

Thedeath toll from coronavirus topped 9,600 in the United States on Saturday,with thenumber of confirmed cases rising to337,000, according to Johns Hopkins University.Worldwide, thevirus haskilled more than 70,000 peopleand sickenedmorethan 1.2 million.

Reusable respirators vs. disposable face masks

Reusablerespiratorsarewidely used in manufacturing andotherindustriesto prevent users from inhaling harmful particles, such as thosefromasbestos.Millions of Americans havethemin their garages and on their workbenches.

Researchers specializing in respiratory protection have foundreusablerespirators,known as elastomerics,arealsoeffectivein health care settingsbecause theyofferthe same protectionas a disposable N95 respirator mask.

Thelogistics aremorecomplicated with thereusable, but thebenefits arethat wevegot protection, and you dont haveto worry about it running out, Pompeii, theBaylor researcher, said.

Themasksarefitted for size, just likethedisposablemasks,toensurea properseal.Theycan bewiped down with hospital-gradedisinfectant wipes between patientsand fully sanitized between shifts. They havecartridges thattrapparticles in theair, includingnano-sized ones, saidStella Hines,a professor and researcher at theUniversity of Maryland School of Medicine.

Thevirus at somepoint will dieon thefilterwerenotexactly surehow long, but within days, saidHines, whohas co-authoredseveralstudies on theuseofelastomeric respiratory masks in health care.

"And then as long as that filter doesnt get damaged by being wet,you should beableto usethat filter for a prolongedperiod of time, shesaid.Oneguidelinesays filters can bechangedevery threemonths, shesaid.

Hines is familiar with the respiratorsnot just through herresearch, but becauseemployees at theUniversity of Maryland Medical Centerusethem.

At thebeginningoftheirshifts,workers sign out masks in their size. Theycleanthemwith hospital-gradedisinfectant wipes between patients. At theend of their shifts, therespiratorsaresanitized, saidJim Chang, director of safety andenvironmental health at themedical center.

Theyrewashed, basically, hesaid.Theyredisinfected, dried, packaged, brought back up to thepoint of distribution and theyregood to go for thenext go-around.

The medical center used reusable masks during the 2009 H1N1 pandemic, Chang said, and learned a lot about how to makethem work. Now, weveput all thoselessons back in use.

Health care industry hasn't adopted reusable respirators

Butelastomericshavenot been widely adopted in thehealth careindustry.According to somestudies,workers saytheyrenot as comfortableas disposablemasks andpatients find themscary-looking. In somecases, workers found itmoredifficultto communicatewith patients.

Pompeiinoted that manufacturers havemodified therespirators to makeiteasier tospeak when wearing them.The masks aremadein colors likepurplish pink.

But thelack of widespread usemay havehampered their inclusion in theStrategic National Stockpile.

KerriWizner, anepidemiologistwithMDGuidelinesand lead author of a 2016 studyexaminingrespiratory protectivedevices andemergency preparedness, said themakeup of any medical stockpileshould reflect whats in use.

They want to stock thethings peopleareusing in hospitals, sotheyrenotgoing, 'Usethis thing thats great, but nobodysever used it,Wiznersaid.Inanemergency situationlikewerehaving rightnow, youdont havetheluxury of setting up this fancy program.

Shortages of masks, ventilators needed to treat coronavirus patients

Officialsacross thecountryareventing aboutshortagesof disposablemasks, ventilators and otherequipmentand spiraling pricesas theycompeteagainst oneanother to buy them.

Its thewild, wild west of personal protectiveequipment, Jared Moskowitz, Floridasemergency management director,said Thursday.

Thestateplaced ordersfordisposablerespiratorsmorethan a monthago, hesaid,buthasntbeen told whenthey will arrive.He's now pleadingwith3M,oneof themanufacturers,to selldirectlyto thestaterather than through a distributor.

Nobody really understands who has product, wheretheproduct is or who represents who, hesaid. Frustration is not theword I would use, but theword I would use,you cant print.

Butat theUniversity of MarylandMedical Center, they facenosuchshortage of respirators.

Themedical centerstockpiledelastomericrespiratorsbefore the H1N1 pandemic in 2009.They wereused regularly fora number ofyears beforethey wereput back in storagefor anemergency,Changsaid. Heserved on a National Academies of Sciences,Engineering, and Medicinepanelin 2017 studying theuseofelastomeric respirators in health care, includingsurgesituations.

Themedical centerordered morewhen COVID-19started to spread across China.When the virus struck the United States, workers were fitted and they were passed out toemployees,Chang said.

Chang saidleadership is key when making decisions about how to preparefor a pandemic likethis.

It becomes incumbent upon peoplelikemyself, otheremergency managers, other safety officers,to then sell it to theinstitutions leadership team, that hey, this is a real problem, weneed to beprepared, and this is what you need to do to beprepared.

Read the original:
Reusable respirators protect doctors and nurses against coronavirus, they aren't in the national stockpile - MetroWest Daily News

Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme & Protein Therapy – 2019 – ResearchAndMarkets.com – Yahoo Finance

The "Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme, and Protein Therapy" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across biosimilars, gene therapy, microbiome, robotics, ribozyme, and protein therapy. The TOE also provides technological analysis for recent developments in animal protein applications, microbiome, and cell cultures.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Recent Advancements in the Biotech Industry

Key Industry Contacts

For more information about this report visit https://www.researchandmarkets.com/r/2q5ocu

View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005525/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the rest here:
Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme & Protein Therapy - 2019 - ResearchAndMarkets.com - Yahoo Finance

University of Tartu researcher to study inequality in prehistoric Europe – Estonian World

To find out about politics and inequality in prehistoric Europe, the European Research Council awarded researchers of three countries with a grant of nearly 2 million; among the scientists to participate in the research is Christiana Scheib of the University of Tartu.

The five-year research is led by John Robb, a professor of European prehistory in the Department of Archaeology at the University of Cambridge.

Robbs project, entitled ANCESTORS Making Ancestors: The Politics of Death in Prehistoric Europe receives 1.94 million in funding. The project takes different methods, developed in previous scientific projects, and applies them to a major theoretical problem in European prehistory the nature of community and the rise of inequality, the University of Tartu said in a statement.

This project is really exciting, and Ill be working with wonderful colleagues, Dr Christiana Freddi Scheib at the University of Tartu and Dr Mary Anne Tafuri at Sapienza University of Rome, Robb said.

Christiana Lyn Scheib, a senior research fellow of ancient DNA in the Institute of Genomics of the University of Tartu, has nearly 700,000 at her disposal in the project. According to her, the grant helps study inequality in prehistoric Europe, which is necessary to understand how our distant ancestors lived and what kind of society they lived in. It will give us information regarding how the organisation of society has changed over time, she noted.

Prehistory denotes the period between the introduction of agriculture and the first written records, according to the university.

In the course of the project, the researchers analyse the DNA, skeletons and funeral customs of 400 people who lived in prehistoric times. The subjects of the research come from three historical periods covering the Neolithic or the Later Stone Age (60004000 BC) and the periods from the end of the Stone Age to Early Bronze Age (40001800 BC) and from Intermediate Bronze Age to Iron Age (1800600 BC).

The results of the analysis enable us, for the first time, to estimate how inequality influenced prehistoric Europe and what the role of our ancestors was in it, Scheib said. No research studies of this kind have ever been conducted.

So far, five researchers of the University of Tartu have received the grant of the European Research Council. Among them, a professor of nanomedicine, Tambet Teesalu, has been awarded the grant twice.

Cover: Christiana Scheib (Lumiere studio).

See the original post:
University of Tartu researcher to study inequality in prehistoric Europe - Estonian World

Hundreds of patients affected by closure of IVF clinics – RTE.ie

A leading fertility specialist has said it is unlikely that IVF treatments will resume in Ireland before June.

Fertility clinics have been closed since the middle of last month leaving hundreds of patients in limbo.

Dr John Kennedy, Group Medical Director of Sims IVF, told RT's Morning Ireland that the cancellation of treatment was "awful", but that it was not possible to keep clinics open and maintain social distancing.

"You can take all the precautions with regard to Personal Protective Equipment (PPE), but it is by no means perfect and if you have a good stockpile of PPE that should probably be in the hands of the general hospitals at this point," he said.

Around 6,000 IVF cycles are undertaken every year in Ireland.

"We generally would have (egg) transfers booked four to six weeks in advance so we had a full transfer list for April.

"That's four or five transfers a day, five days a week. We are having to cancel all of them on a rolling basis so the numbers are mounting up all the time," Dr Kennedy explained.

He said Sims, like other clinics around the country, are still carrying out video consultations and responding to patient queries. However, no clinical procedures are being undertaken.

The initial decision to stop treatment came following advice from the European Society of Human Reproduction and Embryology (ESHRE) on 15 March.

The ESHRE recommendation was based on concerns over the impact of Covid-19 on early pregnancy, however, many IVF patients felt their personal choice was being taken away.

Speaking to RT's Morning Ireland, awoman, who did not want to be named, said:"We have been treated like brood mares. I feel as though my rights, my liberty has been taken away.

"I do not have autonomy over my own body, my own reproductive system. It is abhorrent."

Dr Kennedy described the timeline for reopening clinics as the "million dollar question".

"My gut is telling me nothing good is going to happen in April, it is unlikely something will happen in May, but certainly after that if all the clinics are still closed really everything is going to start to struggle an awful lot."

Caitriona McPartlin, Chief Operating Officer of the ReproMed clinics in Dublin and Galway, said they were attempting to establish protocols to continue to treat patients.

"Once we know that we can open safely following the guidance of the Department of Health, we will do so," she said.

Dr Kennedy said that "in the fullness of time" clinics may have to "live with" additional risks.

"A lot of women that we have are on the clock and as months go by and people get older statistical chances of success drop and that's a terrible thing," he said.

Denise Phillips from Newbridge, Co Kildare, was just about to start a cycle of IVF when she was told the treatment could not proceed.

"It was a big shock because you mentally build yourself up so much that when somebody tells you that you can't go ahead it is just devastating. Beyond devastating."

Denise and her husband, Mark, have a five year-old daughter from a previous IVF treatment and had hoped to expand their family this year.

"I had an initial consultation and was going in to start my scans, get my medication and start our journey but then I got a phone call saying that all IVF cycles were postponed or cancelled.

"Obviously, the Government has to do things that are right, but it's awful for somebody to take away your chance after all that's already been taken from you. What happens if this is around for a long time?"

Denise said that fertility patients are suffering "huge anxiety".

"Their families don't know they are having treatment and they are in isolation. They don't want to leave the house in case they pick up something and then won't be able to get treatment once the clinics reopen. Everyone's mind is racing."

Once fertility services resume, there are concerns over a potential backlog of patients. However, Dr Kennedy said plans are being made to increase opening hours and treatment capacity.

He said: "We are retaining staff and holding on to people so when it comes time to hit the ground running we are in a position to do so.

"It is in everyone's interest to reopen. It will be all hands to the pump."

See original here:
Hundreds of patients affected by closure of IVF clinics - RTE.ie

Opinion | Why panic buying highlights the human need for control and structure – Newcastle Herald

Faith, safety, panic, control

With these uncertain times we saw a spate of panic buying. This got me wondering why humans would react in this way. My first thought was that it was the fear of the unknown. We had little to no information or knowledge of COVID-19, how it could be managed or treated effectively. The only information was on China's experience of the seriousness of COVID-19, its impact on communities and the death rate. With this in mind, and the clearing of essential goods on supermarket shelves, our animal instincts were triggered by what we had control over - protecting ourselves and family by making sure our food and medical reserves were stocked sufficiently when we were in isolation. We were faced with the unknown. The lack of certainty in terms of treatment for the virus as well as limited supplies of essential goods and protective equipment. Why is certainty important? Certainty is the amount of confidence attributed to particular knowledge; like available and effective medical treatment and the replenishing of stocks and supplies to meet demands in a timely manner. The need for certainty is part of the human search for order and security. But certainty is only certainty, as far as it can be. We are certain when we know something is true, and have no doubts. If the facts are unknown, validation is important to convince compliance, in other words 'seeing is believing'. Hence the gathering at the beaches and backyard parties in Bondi instead of practising social distancing. There are seven fundamental human needs and the seventh is subsistence. Maslow's hierarchy of human needs are survival, safety, security, self-care, structure and control. Survival needs include physiological needs such as food, water, air, breathing, excretion, reproduction, warmth, shelter, rest, sleep, homeostasis, etc. Safety and security needs include personal security, work, resources, property, and health. Self-care needs include things like leisure, entertainment, healthcare, etc. Subsistence includes everything needed to sustain life. Individuals also need control and structure their lives to make them feel safe and secure. According to research by Dr Lauren Leotti and her colleagues, "the need for control is a biological imperative for survival". Globally, COVID-19 is affecting our physical and psychological health and safety. People are losing their jobs, essential services are stretched with limited resources, and fatigue management is non-existent. With lockdown and indefinite isolation, humans may develop cabin fever and begin to feel stressed and anxious. To get through this outbreak, communication and connectivity is essential among colleagues. It provides support and unity in these times of isolation and uncertainty. Faith Eeson is a safety consultant with FOCCALE Safety Management

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/SZjBdCvXzdW4Ygt94axh3r/f65e6ef0-4127-44c6-a6f2-61e3052ef008.JPG/r0_183_1192_856_w1200_h678_fmax.jpg

OPINION

April 6 2020 - 8:00PM

Faith Eeson

With these uncertain times we saw a spate of panic buying. This got me wondering why humans would react in this way.

My first thought was that it was the fear of the unknown. We had little to no information or knowledge of COVID-19, how it could be managed or treated effectively. The only information was on China's experience of the seriousness of COVID-19, its impact on communities and the death rate.

With this in mind, and the clearing of essential goods on supermarket shelves, our animal instincts were triggered by what we had control over - protecting ourselves and family by making sure our food and medical reserves were stocked sufficiently when we were in isolation.

We were faced with the unknown. The lack of certainty in terms of treatment for the virus as well as limited supplies of essential goods and protective equipment.

Why is certainty important?

Certainty is the amount of confidence attributed to particular knowledge; like available and effective medical treatment and the replenishing of stocks and supplies to meet demands in a timely manner. The need for certainty is part of the human search for order and security. But certainty is only certainty, as far as it can be. We are certain when we know something is true, and have no doubts. If the facts are unknown, validation is important to convince compliance, in other words 'seeing is believing'. Hence the gathering at the beaches and backyard parties in Bondi instead of practising social distancing.

There are seven fundamental human needs and the seventhissubsistence.

Maslow's hierarchy of human needs are survival, safety, security, self-care, structure and control. Survival needs include physiological needs such as food, water, air, breathing, excretion, reproduction, warmth, shelter, rest, sleep, homeostasis, etc. Safety and security needs include personal security, work, resources, property, and health. Self-care needs include things like leisure, entertainment, healthcare, etc. Subsistence includes everything needed to sustain life.

Individuals also need control and structure their lives to make them feel safe and secure.

According to research by Dr Lauren Leotti and her colleagues, "the need for control is a biological imperative for survival".

Globally, COVID-19 is affecting our physical and psychological health and safety. People are losing their jobs, essential services are stretched with limited resources, and fatigue management is non-existent.

With lockdown and indefinite isolation, humans may develop cabin fever and begin to feel stressed and anxious.

To get through this outbreak, communication and connectivity is essential among colleagues. It provides support and unity in these times of isolation and uncertainty.

Faith Eeson is a safety consultant with FOCCALE Safety Management

Read the original:
Opinion | Why panic buying highlights the human need for control and structure - Newcastle Herald

Coronavirus is growing exponentially here’s what the numbers mean – The Next Web

You may have seen a version of the infographic (below) that explains the potential impact of social distancing. It nicely illustrates that reducing the total number of disease-spreading contacts each infected person has can have a dramatic effect on the total number of infections a short time later. The numbers rely on the mathematical concept of exponential growth.

The total number of infected people reduces dramatically after 60 days with relatively small changes to the reproduction number of the disease. Christian Yates, Author provided

Recently, Boris Johnson, the British prime minister, told the press that it looks as though were now approaching the fast growth part of the upward curve. And without drastic action, cases could double every five or six days. The consistent doubling of cases in a fixed period is the hallmark of exponential growth.

The number of new infections that a single infectious individual will cause during their infectious period is known as the basic reproduction number of a disease. This number is key to determining how widespread a disease will become.

For COVID-19, early estimates of the basic reproduction number have it somewhere between 1.5 and 4. The infographic assumes a figure somewhere in the middle, at 2.5 infectious contacts per infectious individual.

If the reproduction number of a disease can be brought below one, then the spread will slow until the disease dies out. The revised infographic below shows the number of currently infected people. Reducing contact with others by 75% will bring the reproduction number below the critical level, allowing the number of infected people to decrease almost to zero in just two months.

The number of currently infected people after 60 days (assuming recovery after 10 days) changes with the reproduction number of the disease. Christian Yates, Author provided

However, the basic reproduction number of the current stage of the outbreak is way above one. This means that each newly infected person will pass on the disease to at least one more person, on average, and consequently the disease will take off exponentially.

But what, precisely, is exponential growth? The mathematical definition says that a quantity that increases with a rate proportional to its current size will grow exponentially. This means that as the quantity increases so does that rate at which it grows. The more infected people we have in the early stages of a disease outbreak, the more people they will infect and the more the cases will rise.

The total number of confirmed cases of COVID-19 in the UK is increasing exponentially. Max Roser, Hannah Ritchie and Esteban Ortiz-Ospina (2020) Coronavirus Disease (COVID-19) Statistics and Research, CC BY

Other situations in which exponential growth plays a critical role range from pyramid schemes to nuclear weapons. In a pyramid scheme, each new investor invites two more recruits who in turn invite two more. This rapid growth, at a rate proportional to the current number of members, inevitably leads to a situation in which there arent enough new recruits to keep the scheme going and it eventually collapses. When the pyramid tumbles, most investors lose their money.

In a nuclear fission bomb, a single uranium atom splits in two, jettisoning fast-moving neutrons and large quantities of energy in the form of electromagnetic radiation. The neutrons then collide with more atomic nuclei, splitting more atoms and releasing yet more energy in a nuclear chain reaction that increases exponentially.

At about 8:15 in the morning of August 6 1945, the atomic bomb known as the Little Boy detonated releasing energy equivalent to 30 million sticks of dynamite in an instant, devastating the Japanese city of Hiroshima. The surrender of Imperial Japan was announced nine days later. This is the awesome power of exponential growth.

Although the concept of exponential growth is not new in the public consciousness, a lot of misconceptions surround the idea. Exponential is often used as a byword for rapid or large. As a counterpoint, consider the money in your bank account. Provided the interest is compounded (that is, interest is added to your initial amount and earns interest itself) then the total amount of money in your account increases in proportion to its current size the hallmark of exponential growth.

As Benjamin Franklin put it: Money makes money, and the money that money makes, makes more money. If you could wait long enough, even the smallest investment would become a fortune. But dont lock up your rainy-day fund just yet. If you invested 100 at 1% per year it would take you over 900 years to become a millionaire. Very few people would accuse the exponential growth associated with their bank account of being large or rapid.

So exponential growth does not necessarily deal with big quantities, and it is not necessarily fast. Unfortunately, across a wide range of different countries, the term exponential is appropriate to describe the rapid spread of SARS-CoV-2, the virus that causes COVID-19. With cases doubling every three to four days in the UK and deaths doubling every two to three days, things could get ugly quickly.

One small crumb of comfort is that almost nothing can grow exponentially forever. The only exception, ironically, is the all-too-slow growth of money in your bank account, which, at least on paper, could grow indefinitely. Unfortunately, COVID-19 cases dont have to grow exponentially forever, or even for much longer, before the disease becomes one of the most devastating pandemics the world has ever seen.

Because the exponential proliferation of the disease is so undeniably dramatic, any changes we can make at this relatively early stage can make a huge difference even a few days down the line. Now is the time to act, to double down on our containment efforts to bring the exponential spread under control.

This article is republished from The ConversationbyChristian Yates, Senior Lecturer in Mathematical Biology, University of Bathunder a Creative Commons license. Read the original article.

Read next: Polish electric vehicle advocate lobbies for EV emoji, because why not?

Read our daily coverage on how the tech industry is responding to the coronavirus and subscribe to our weekly newsletter Coronavirus in Context.

For tips and tricks on working remotely, check out our Growth Quarters articles here or follow us on Twitter.

More:
Coronavirus is growing exponentially here's what the numbers mean - The Next Web

When research on the water turns to gold – Calvin News

When Laura Dykstra was finishing up high school, she had research on her mind. Dykstra, from West Chester, Ohio, saw opportunity just a few hours to the north.

There are a lot of diverse ecosystems and wildlife species in Michigan and the Great Lakes area, and I thought it would be great to study them in person, said Dykstra.

So, she visited some schools, looking for an opportunity to get started.

Calvin was one of her stops.

I was impressed by all of the research opportunities at Calvin even freshmen are able to get involved in the lab or in the field, said Dykstra.

It didnt take Dykstra long to realize the unique opportunity she would have at Calvin to pursue her dream. So, she chose Calvin, and with the help of her professors she was plugged into research right away.

One of the greatest things about Calvin is how much the professors are invested in their students; I feel like Ive gotten to know my professors well and that they care about my career goals, said Dykstra, a biology major.

Along with two other undergraduate students, Dykstra is working in biology professor Keith Grasmans lab. They are monitoring the impact of environmental contaminants on the health of Great Lakes colonial waterbirds.

Following World War II, industrial and agricultural activity introduced high concentrations of pollutants into the Great Lakes ecosystem. These chemicals persist in the environment and bioaccumulate in organisms at higher trophic levels, including fish-eating birds. Since contaminants are associated with poor reproduction, reduced chick survival, immune suppression, and deformities in fish-eating birds, gulls and terns are effective indicators of contamination in the Great Lakes.

In the summer, we travel to herring gull and Caspian tern colonies at contaminated sites in Michigan, including Saginaw Bay, Grand Traverse Bay, and the River Raisin in Monroe, said Dykstra. At the colonies, we measure egg size, embryo viability, nest productivity, chick growth, and chick immune function.

I appreciate that Im involved in every aspect of the research: preparing for fieldwork, collecting data, and analyzing that data, said Dykstra. Thats a unique experience for an undergrad to have.

Dykstras experiences at Calvin have led to some important discoveries.

Our research has found that chicks at contaminated colonies continue to show reproductive, growth, and immunological impairments, which informs U.S. Fish & Wildlife remediation efforts at these sites.

And these discoveries have led to bigger platform

Dykstra, in her third year at Calvin, has already presented posters at the Society of Environmental Toxicology and Chemistrys North America Meetings in 2018 in Sacramento, California, and in 2019 in Toronto, Canada.

She also works with a group studying suburban red-shouldered hawks and recently published an article in the Journal of Raptor Research titled Red-Shouldered Hawks Banded in Suburban Southern Ohio, 1996-2018. And she has another submitted paper that is still under review.

These experiences have set Dykstra up for her crowning achievement at Calvin. In late March, Dykstra was awarded a Goldwater Scholarshipwidely considered the top research award for undergraduate students in the sciences. Only 396 college students across the United States received this honor in 2020-2021. The scholarship, a partnership between the Barry Goldwater Scholarship and Excellence in Education Foundation and the Department of Defense National Defense Education Programs, comes with a $7,500 scholarship to support students in their research journeys.

The Goldwater opens up opportunities for studying in the future, said Dykstra.

For Dykstra, that means more opportunities to do what she loves: research!

And with the research experience she has had at Calvin, and the prestigious Goldwater honor, she should have her pick at where she wants to go to graduate school to study Wildlife Ecology.

Im most interested in wildlife conservation, Im hoping to work in academia or in a government agency, said Dykstra. Im interested in how anthropogenic activity affects wildlife, and how our work can influence policies that protect the environment and human health.

Read the original here:
When research on the water turns to gold - Calvin News

Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study -…

Study design

The present study is a retrospective cohort study (Trial registration: ChiCTR-OOC-14005389, 2014). In this study, 321 PCOS cases was conducted from October 2015 to April 2017 to assess the effect of short-term vitamin E administration on infertile PCOS women undergoing ovulation induction with CC and HMG in the Reproductive Medicine Center, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. This retrospective cohort study was approved by the Institutional Review Board of the Department of Chinese Medicine Hospital of Jiangsu Province.

The inclusion criteria of this study were as follows: (i) Undergoing ovulation induction with CC and HMG; (ii) no previous infertile treatment; (iii) age less than 40 years; (iv) normal in hysterosalpingography; and (v) normal in semen analysis. The diagnostic criteria of PCOS was according to the 2006 Rotterdam criteria [17]: (1) Anovulation or olig-ovulation, (2) Clinical evidence of hyperandrogenism (on the basis of hirsutism or an elevated testosterone level), (3) Polycystic ovaries (a more than 10ml ovarian volume or at least 12 antral follicles with 29mm in diameter). PCOS could be confirmed if any 2 out of the following 3 criteria were met and if any other diseases that caused hyperandrogenism or anovulation could be excluded.

Other disorders that mimic the PCOS, including hyperprolactinemia, thyroid disease, late-onset congenital adrenal hyperplasia, androgen-secreting tumors and Cushings syndrome were ruled out. The PCOS patients with the major myocardial, liver and renal disorders, and taking confounding medications (primarily sex steroids, other infertility drugs, and insulin sensitizers) were excluded. Patients were divided into 3 groups according to the vitamin E used.

In this study, as shown in Fig. 1a, 110 of 321 PCOS cases underwent controlled ovarian stimulation but without vitamin E administration (Group A, n=110). Based on previous clinical medication experience, a dosage of 100mg/day vitamin was selected. Two-hundred eleven of or 321 PCOS cases underwent controlled ovarian stimulation combined with vitamin E administration (100mg/day, p.o.) started from follicular phase (Group B, n=105) and luteal phase (Group C, n=106), respectively. Administration of vitamin E in follicular phase(Group B) began from the 3rd day of the menstrual cycle to 14th day of luteal phase. Administration of vitamin E in luteal phase (Group C) started when ovulation was confirmed, and lasted for 14 consecutive days. After 14days of the HCG administration, serum -HCG was measured. The presence of a gestational sac on ultrasound was performed at 6 and 12weeks of gestational age to determine clinical pregnancy rate and ongoing pregnancy. The women enrolled in this study were followed up until miscarriage or delivery.

Summary of patient flow diagram a and Vitamin E administration and stimulation protocol b. EV=estradiol valerate; HCG=urinary human chorionic gonadotropin; Pg=progesterone;CC=clomiphene citrate;VE=vitamin E;TVU=Transvaginal ultrasonography; HMG=human menopausal gonadotropin

As shown in Fig. 1b, the ovulation was stimulated with CC (Merck Serano, China) at 100mg/day for 5days starting on day 3 of a spontaneous menstrual cycle or withdrawal bleeding. Starting from day 8, HMG (Livzon, China) was injected at 75IU every second day and estradiol valerate (Progynova, Bayer, China) was administered at 2mg/day. Transvaginal ultrasonography was performed from day 10 to adjust the HMG dosage. When at least one follicle had reached a diameter of 18mm, 10,000IU urinary human chorionic gonadotropin (hCG) (Livzon, China) was administered. All patients received luteal phase support by oral administration of progesterone (Dydrogesterone, Abbott Biologicals B.V, China) at 10mg three time a day for 14days starting on the day of ovulation. In each cycle, medroxyprogesterone acetate was used to induce withdrawal bleeding in cases in which there was no response. The complete participation considered as pregnancy or anovulation within a total of 6 cycles.

Body mass index (BMI) was used to evaluate the body weight. According to World Health Organization(WHO) criteria [18], women with a BMI <18.5, 18.525, 2529 and30kg/m2 were defined as underweight, normal weight, overweight and obese, respectively. Scores on the modified FerrimanGallwey scale [19], range from 0 to 36, were used for hirsutism evaluation. Higher scores indicated a greater degree of hirsutism.

Age, height, weight, waist, FerrimanGallwey hirsutism score, age of menarche, incidence of oligomenorrhea and amenorrhea, numbers of previous pregnancies and previous ovarian were obtained from patient medical records.

Levels of estradiol (E2), androstenedione (T), luteinizing hormone (LH), prolactine (PRL) and follicle-stimulating hormone (FSH) were tested by RIA (Beijing North Institute of Biological Technology of China and the CIS Company of France). Peripheral blood samples were taken on the 3th day of menstrual cycle after overnight fasting.

In this study, we measured four oxidative stress serum markers (malondialdehyde (MDA), ischemia modified albumin (IMA), total antioxidant capacity measurements (TAC), and vitamin E) in 3 time points (T0:before stimulation, T1: the day of HCG treatment, and T2: the day of complete participation) to evaluate the levels of oxidative stress. Serum levels of MAD, an end-product formed during lipid peroxidation that is released into the extracellular space and finally appears in the blood [20], were measured using a thiobarbituric acid-reactive commercial kit (Jiancheng Bioengineering Institute, China). Serum TAC, provided better information on antioxidant status than individual antioxidant compounds [21], were tested using an antioxidant assay kit (Jiancheng Bioengineering Institute, China). Serum levels of IMA, a novel marker of oxidative stress, were evaluated by cobalt to albumin binding capacity kit (CUSABIO, China). Serum contents of vitamin E were evaluated by colorimetric method using assay kit (Jiancheng Bioengineering Institute, China).

Statistical analysis was carried out by SPSS (version 23, USA). Data were presented as either median (Min-Max) or meanSD as appropriate. Quantitative data analyses were carried out by independent samples t-test or Mann-Whitney U-test depending on the normality of data. Categorical variables were compared with Chi-Square test. A P value <0.05 was considered as statistically significant.

See original here:
Effect of a short-term vitamin E supplementation on oxidative stress in infertile PCOS women under ovulation induction: a retrospective cohort study -...

The traffic light exit strategy to free the UK from lockdown – The Guardian

Britain has been in lockdown for two weeks and it has been the grimmest of fortnights. The number of daily deaths from Covid-19 has continued to rise steadily and large chunks of the economy have been brought to a standstill.

As yet, there are few hard numbers to judge the economic impact, but the collapse seen in the past few weeks is without precedent both in its speed and its severity. The increase in the numbers applying for universal credit suggest that unemployment is rising rapidly despite the government schemes to support both the employed and the self-employed.

The aim of the Treasury and the Bank of England is to get the UK through the crisis with a minimum of scarring. Hence there are loan guarantees designed to prevent businesses that were perfectly viable a month ago from going bust as a result of the shutdown. The hope is that wage subsidies will prevent workers from losing touch with the labour market and becoming long-term unemployed.

But clearly the longer it takes to tackle the health emergency the greater the economic damage will be. A 20% drop in output in one quarter a perfectly feasible possibility would be bad enough, but what if the lockdown were extended into the summer or the autumn?

Mervyn King, the former governor of the Bank of England, said last week that it was unrealistic for the government to keep the lockdown in place indefinitely and that if it went on for months on end there would be a rebellion against it.

That assessment is almost certainly right. The government does need an exit strategy but it is also being warned by epidemiologists that if the restrictions are relaxed too soon the virus could return. A second lockdown would not just be hugely unpopular, it would also magnify the economic damage.

The government says any decisions it takes on ending the lockdown will be based on science, but the scientists dont always agree. Thats because they are using models and these have limitations. Why? Because the results of epidemiological models depend on what is fed into them, and this requires the scientists to make a number of assumptions about human behaviour.

This is a point made by Gerard Lyons and Paul Ormerod in an important new paper that might just offer the government the sort of exit strategy that King was talking about.

Lyons and Ormerod do not dispute that a lockdown was necessary. Indeed, they think that the governments initial idea that the population would develop herd immunity to the virus was dangerous nonsense.

The evidence from other countries is that social distancing, shutting the restaurants and bars, discouraging unnecessary travel and getting people to work from home if they can does have an impact.

Before the lockdown began, estimates suggested that on average each person with the virus infected between two and 3.5 other people. Without action, the virus would have carried on spreading, putting intolerable pressure on the NHS and killing many more people. This is known as the reproduction number: if it is above one, someone who is infected will pass it on to more than one person. If it less than one, it will fade away. The experience of China and Italy is that lockdowns will get the reproduction number below one.

But the danger is that the reproduction number could go back up again if Britain went straight back to business as usual the moment the lockdown restrictions were lifted. If people celebrated en masse by going to the pub, to the football or by having a street party, there would be risk that the reproduction number would go up again and the virus would return. It is this possibility that concerns the epidemiologists.

Taken to extremes, this would involve continuing the lockdown until there was no longer a risk of someone with the virus infecting anyone else and so ensuring that no one dies. But as Lyons and Ormerod points out, a similar approach would involve the banning of all road traffic to prevent the nearly 2,000 deaths a year on the road in Britain.

Instead, they suggest that the return to normal life takes place under a traffic light system that will exploit the fact that people are going to be a lot more cautious in their behaviour after the crisis than they were before.

If people revert very quickly to the patterns of behaviour before the crisis, the epidemiological models are correct. There would be a second wave of infections. But behaviour will be different, either because of the lessons people have learned during this crisis, or because of the constraints placed upon them by rules and regulations.

The paper suggests that phase one of the process involves moving from lockdown to red. In this period, more but not all shops would open and they would have to observe the strict social distancing currently seen in supermarkets. Travel would be discouraged and many international flights banned.

In the amber phase, unlimited car journeys would be allowed, and the wearing of face masks and disposable gloves would be mandatory on public transport. Restaurants would be allowed to open only if they had strict seating demarcations to keep people at a safe distance.

It would only be when the light turned to green that any sort of sporting event or other mass gatherings, such as music festivals could take place, and the churches, temples and mosques open their doors.

Inevitably there will be those with different views about what should be included in the red, amber and green phases. But its worth noting that Lyons was once an adviser to Boris Johnson when he was mayor of London. The prime minister might just be listening.

Read more here:
The traffic light exit strategy to free the UK from lockdown - The Guardian

Strategies that can be used to fight Covid-19; their merits and demerits – Standard Digital

Epidemiologists measure how a disease spreads through a population using the basic reproduction number, otherwise known as R0. Typical seasonal flu has an R0 of 1.2, while that of Covid-19 is reported to be approximately 2.5.R = Reproductive number: How many people a given patient is likely to infect. If R >1, each case on average is giving it to at least one other person. The epidemic will increase. R0 is affected by factors like population density, environment, host factors (age, immunity), etc. Typical seasonal flu has an R0 of 1.2, Spanish Flu had an R0 of 2-3, while that of Covid-19 is reported to be approx. 2.5. From a policy planning perspective, it offers a very clear objective: Reduce R

SEE ALSO: Japan cruise ship coronavirus cases climb to 174

For More of This and Other Stories, Grab Your Copy of the Standard Newspaper. Read Now

SEE ALSO: New China virus cases drop for third day as toll passes 1,600

SEE ALSO: China leader Xi Jinping knew about coronavirus scale much earlier than believed

SEE ALSO: Americans arrive home from virus-infected cruise ship

Do not miss out on the latest news. Join the Standard Digital Telegram channel HERE.

Read the original here:
Strategies that can be used to fight Covid-19; their merits and demerits - Standard Digital

Who will be next to join Flyers immortality? – South Philly Review

Two years ago, Eric Lindross No. 88 was raised to the rafters of the Wells Fargo Center as the dynamic center and former hockey child prodigy became the sixth Flyer to have his number retired.

Some, including maybe Lindros himself, thought the day might never come, as his well-documented disputes with former general manager Bobby Clarke at times seemed irreparable.

Bygones eventually became bygones and Lindros joined Bernie Parent, Mark Howe, Barry Ashbee, Bill Barber and Clarke himself in Flyers immortality.

Whos next?

Should there be a next?

You could argue that the Flyers six retired numbers sounds just about right for a franchise that is 52 years old and has won two Stanley Cups. In fact, the Los Angeles Kings and Dallas Stars (formerly Minnesota North Stars), which each entered the league at the same time the Flyers did, will each have six retired numbers once Sergei Zubovs 56 jersey gets raised next season in the Lone Star State.

The St. Louis Blues, also an original expansion team, will have eight retired numbers when Chris Prongers No. 44 is raised next year. The Pittsburgh Pittsburgh, another 1967 expansion team, somehow have only two retired numbers despite five Stanley Cups. Obviously, Nos. 87 and 71 will be added when Sidney Crosby and Evgeni Malkin are finished being Flyers nightmares.

But should those ratios matter? The Buffalo Sabres have seven retired numbers, and the Vancouver Canucks have six despite never winning the Cup and having a slightly shorter history than Philly.

A decent case could be made for several former Flyers, and maybe a few current players, to be the next guy.

Before we dive deep, a few honorable mentions should be named before reaching the top five. Those would be John LeClair, Simon Gagne, Tim Kerr, Reggie Leach and Eric Desjardins. All were great players and are in the Flyers Hall of Fame with the exception of Gagne, whose name should be called soon.

Here are the five with the best odds of being the next Flyer to have his number retired, in alphabetical order.

Claude Giroux If his time with the Flyers ended today, Giroux falls short. But he still holds his destiny in his own hands. Think about if the Flyers do win a Stanley Cup in the next few years and Giroux is the captain who ends a 40-something-year drought the way Mark Messier ended 54 years of torture in New York.

Giroux is currently third in games played in team history, second in assists and fourth in points. By the time he retires, he could be the only player besides Bobby Clarke to finish with 1,000 games and 1,000 points in a Flyers uniform. Bonus points if he ends his career here.

Ron Hextall This is another guy whose story hasnt quite reached completion. Holding the most wins in franchise history (240), Hextall is regarded as the second-best Flyers goalie behind Parent and won the Vezina and Conn Smythe trophies during his time here while taking the Flyers to the Stanley Cup Finals twice.

The second phase of his hockey career was his stint as general manager of the team just a few years ago. Drafting players such as Travis Konecny, Ivan Provorov, Travis Sanheim, Oskar Lindblom, Nolan Patrick, Joel Farabee, Morgan Frost and Carter Hart have set the Flyers up for success. If the team wins a Stanley Cup soon, Hextalls fingerprints will be all over the blueprints.

Rick MacLeish The sun is getting pretty low for the Broad Street Bullies-era guys but MacLeish is still worth mentioning. MacLeish, who died in 2016 at 66, was best known for his performance during both postseasons in which the Flyers won the Stanley Cup, scoring 42 points in 34 games during those two runs. He played in 741 regular season games over a dozen years in Philadelphia and ranks sixth in goals (328) and fifth in points (697).

Perhaps overshadowed by other local heroes of that era, MacLeish never really got the appreciation he deserved. Its now been 36 years since he last played, which probably means the case is closed on MacLeish.

Brian Propp When you talk about stats, Propps jump off the page. In 11 years in Philly, Propp amassed 369 goals, 480 assists and 849 points and was a plus-299 during his time here.

Hes second only to Bill Barber in goals as a Flyer and is a top five in almost every major statistical category. More recently, Propp learned to walk again after recovering from a massive stroke in 2015 and remains a pillar in local philanthropy and a friendly face at Flyers alumni events.

If you need an inspirational hero, look no further.

Mark Recchi Years ago, Recchi might have been considered a long shot, as most of his success had come elsewhere, winning Cups in Pittsburgh, Carolina and Boston. But Recchi was inducted into the Hockey Hall of Fame in 2017 and played the largest chunk of his career in Philadelphia, which included two stints. Having played for seven NHL teams, Recchis only chance at number retirement is likely in Philadelphia, although only 627 of his 1,533 career points were collected here.

Recchis 123 points during the 1992-93 season remains a team record, and he followed it with 107 points the following year.

Go here to read the rest:
Who will be next to join Flyers immortality? - South Philly Review

Opossums, Hydras And Hummingbirds: What We’re Learning About Aging From Animals | NPR – KCRW

Written by Lulu Miller, Elena Renken Apr. 06, 2020

A stint as lion tamer in Hollywood got Steven Austad interested in animal biology. And soon he turned from training animals to studying them. He's now chair of the biology department at the University of Alabama at Birmingham, where his research focuses on aging.

He's learned that aging happens at different rates in different animals, without following any clear rules. Austad says it's not heart rate that predicts lifespan. An animal's size has something to do with it, but some animals defy that pattern. And even more perplexing are animals that don't seem to age at all like a tiny sea creature called a hydra.

Austad spoke with Invisibilia's Lulu Miller to discuss what science has uncovered about animal aging processes, and how researchers might be able to use what they've learned to extend human lifespans. There's no immortality on the horizon or anything close to it but it's likely science can eventually lengthen our lives by at least a little, Austad says.

This interview has been edited for clarity and length.

How did you go from lion taming for the movies to studying aging?

I was a reporter for the Oregonian newspaper in Portland. And a friend of mine had a couple of African lions for pets, because he was crazy. He got an offer to use them in a movie, and he needed somebody to help him transport them from Portland to Hollywood. And he talked me into helping out. When I got down there, the movie producer offered me a job and I said, "You understand I don't know anything at all about this, right?" And he said, "that's okay." It awakened my interest in animals and what makes animals tick. After I got fairly seriously injured one time, I thought maybe this is not really what I want to do the rest of my life. So I decided to study animals in graduate school.

What did you like about training lions?

What I liked the most about lions is because they live in social groups, they like contact. They're almost like dogs, more like dogs than cats, except they sometimes will try to kill you. But I just love the intimate contact with them. For the first year, I never took a day off. I worked seven days a week.

How did opossums' short life span get you interested in longevity?

We were working on some animals in South America opossums. I discovered that they age really quickly, almost like mice. And that was so puzzling to me that I completely abandoned what I was working on. It was the size and the longevity combination. I think we all have this kind of intuitive feel from being around animals that smaller animals are going to [have] shorter lives. So you know, a dog has a longer life than a mouse, and a horse has a longer life than a dog, and an elephant has a longer life than a horse. And this just seemed to grossly violate that. I had to recapture them every month, and I would come upon one that was in prime physical health, and two months later it would have cataracts, and it would have lost muscles, and had parasites all over it, and arthritis. It all happened so abruptly.

So, are size and lifespan linked in animals or not?

Yeah, it's a very general pattern. It's true of mammals. It's true of birds. It's true of reptiles. It's true of almost every group of animals. We know that smaller ones are shorter-lived and bigger ones are longer-lived. But there are exceptions, and actually I think the exceptions are the ones that are most interesting from a scientific perspective.

What is the billion beats hypothesis and why do you question it?

I've spent a good deal of my career trying to kill it, but obviously, I haven't been able to. The [idea] is that life is inherently destructive and that burning energy is inherently destructive. Let's say all mammals have a kind of a fixed amount of energy that they can burn over the course of a lifetime. And if they burn it fast, they'll be short-lived, like mice. And if they burn it slow like an elephant, they can live much longer than that. If you actually look at a whole bunch of animals, it turns out that smaller ones actually have more heartbeats and use more energy over the course of a lifetime than large ones.

And then there are these massive exceptions to it. Hummingbirds have a heart rate of over 1,200 beats per minute, which is kind of like a machine gun, but yet they can live in the wild into their teens.

And there's a very small animal that's actually one of the longest lived creatures, right?

Hydras were discovered actually in the early 1700s by Van Leeuwenhoek, who invented the first decent microscope. They're freshwater animals, maybe a quarter to a half inch in length. They almost look like a sea anemone, they're just smaller and skinnier. They really started to be studied in earnest a few years later by a Swiss biologist named Trembley who discovered if he cut them in half across the middle, the bottom would grow a new top, and the top would grow a new bottom. It turns out that you can even treat them with chemicals that basically dissolve all the things that make their cells stick together. You'd make a pile of cells and they will eventually reassemble into a hydra. He started chopping them up in all kinds of ways to see exactly what you needed to regenerate. He eventually created a hydra that had multiple heads. That's how it really came to be [called a] hydra, because a hydra in Greek mythology was this monster that had many heads.

And what did we learn about aging from the hydra? How is it even possible for them to have this kind of longevity?

Hydras have stem cells in them. When they divide, one half of it remains a stem cell, but the other half will eventually turn into part of the tentacle or part of the mouth or part of the body wall. It changed the way we thought about animal development at that point in time. We didn't really know how animals develop [in the 1700s], and one idea was that animals were just very, very tiny replicas of themselves when they were in an embryonic stage, and that pre-formed thing just grew. At that point they thought, maybe inside of a human egg there's a little tiny human and it hatches out into a baby and then it just grows and grows and grows. The hydra pretty much killed that idea because we could take just part of it, which clearly did not contain a whole hydra, and grow a whole new hydra out of it.

Are hydras really immortal?

Rumors really started to accumulate in the 1950s. People had followed individual hydras for a few years, and they didn't seem to die at any higher rates. So there was a rumor that they might be potentially immortal. Daniel Martnez in the late 1990s actually reported that they didn't age. Few people believed him.

At least for as long as anybody's had the patience to follow individual hydras that has been about seven years at the most there's no indication that they age at all. It is possible that if we followed them long enough, we would discover that they aged, but no one has had the patience to do it. Certainly it would be a very, very long time. They're not the only animal that doesn't age, but they're one of the few, and the others that don't appear to age are really close relatives the various kinds of jellyfish, for instance.

What has been unlocked in the science of aging by looking at hydras?

So the idea that if you manipulate single genes, it can have a dramatic effect on aging was really discovered in the late 1980s I would say. And then through the 90s it was confirmed and other genes were discovered.

One of those genes directly interacted with this gene FOXO. Finding this in everything from little worms to people [with long lifespans] suggested that the activity of FOXO might be a key to understanding slow aging. So the hydra work really confirmed what had been seen in a number of other animals.

How has research on slowing aging progressed?

Starting about 30 years ago, people discovered that there were genes that if you either knocked down their activity or souped up their activity could really have a major impact on aging. We started to look at drugs that could affect aging, and we now have at least half a dozen drugs that we know affect aging in a lot of different animals. Some of those things will turn out not to work in humans, but I'm quite confident that we will develop ways to improve human health either by injections, by transfusions, by taking certain pills every day. And that's what the biotech industry is going nuts with right now.

You often hear people fantasize that we're going to live 500 or 1,000 years in the future, and I don't buy that at all. We haven't been able to do that with different species. What we can do is we can increase the longevity of mice, worms and flies let's say by 20% many, many ways. And so I think that's a reasonable idea. What's unclear is how much of that will be healthy life.

Are there drawbacks to potentially extending lifespan?

Let's imagine that we discover a gene mutation that doubles lifespan. If this is so great, why didn't nature do this a long time ago? If it has an effect on reproduction or the [time] to sexual maturity, it may turn out from an evolutionary standpoint not to be a good gene, but to be a bad gene. For all of the benefits that we get in terms of health, there may be some downsides to some of these treatments. We need to be careful.

Knowing everything you do about aging, do you live any differently?

I don't take anything. I don't do any weird diets. I do a lot of sensible stuff. I exercise a lot. I eat right. I don't smoke. Once there's enough evidence, I may try some other stuff. I don't think there's evidence enough in humans to be doing anything else right now.

Here is the original post:
Opossums, Hydras And Hummingbirds: What We're Learning About Aging From Animals | NPR - KCRW

Teen paperboy with vampire obsession ripped elderly woman’s heart out and drank her blood to be immortal – MEAWW

A teenage boy who was obsessed with vampires killed an elderly woman, 90, ripped her heart out and drank her blood.

Channel 5's new documentary series 'The Kids Who Kill' looks at the case of Matthew Hardman who had committed one of the most gruesome murders in the UK's legal history in 2001. Hardman was 17 at the time he murdered Mabel Leyshon as he believed he would become immortal.

The documentary looks at the brutality of Hardman's crimes against the pensioner.

The sickening murder took place on the island of Anglesey in North Wales. The crime came as a huge shock to those who knew the boy and describe him as 'remarkably normal'. Hardman was a paperboy and Leyshon knew him. He broke into the elderly woman's home while she was watching tv.

He stabbed Leyshon around 22 times and cut open her chest to remove her heart and drank blood from it.

He then laid down two pokers in a cross shape by her feet. Her body was found two days later.

Hardman had earlier been an art student and had also attacked a German exchange student after she refused to bite him on the neck to make him immortal. The twisted teen had also told the authorities that old people were the kind to have their blood drunk by vampires.

It came to be known that Harman had been smoking cannabis and had been searching through the internet for "vampires, gothic flesh-eating and other macabre things." According to detective Sgt. Lestyn Davies, Hardman had "this deep-rooted insanity".

"He believed if he murdered this old lady of 90, disemboweled her, ripped her heart out and drank her blood, he would be a vampire forever," he shared. "Now, to believe that is insane. He was one of the most violent evil offenders that I have dealt with."

"If he had got away with it, if we had not discovered him, he could have gone on and committed further horrendous crimes," detective Supt Jones revealed. People who knew him had begun to see a change in him. He had developed a fixation on vampires and had started to believe that they may actually exist in reality.

During his trial, the prosecution barrister explained that Hardman "believed they existed, believed they drank human blood and believed most importantly that they could achieve immortality." There was overwhelming evidence that Hardman had committed the crime.

He had left a lot of DNA trail on the scene and had also stored the murder weapon with traces of Leyshon's blood in his bedroom. He was convicted and sentenced to prison for life at the Mold Crown Couty in 2002. At the sentencing, Judge Richards had shared there was enough evidence to indicate that Hardman believed that he could achieve immortality by killing Leyshon and drinking her blood.

Justice Richards said, "You have been convicted by the jury on the strength of the most compelling evidence. The horrific nature of this murder was plain to all. It was a vicious and sustained attack on a vulnerable old lady in her own home, aggravated by the mutilation of her body after she had been killed."

"It was planned and carefully calculated. You hoped for immortality but all you have achieved is the brutal ending of another person's life and the bringing of a life sentence upon yourself," Daily Mail reports.

The rest is here:
Teen paperboy with vampire obsession ripped elderly woman's heart out and drank her blood to be immortal - MEAWW